By comparative DNA fingerprinting, we identified a 357-bp DNA fragment frequently amplified in esophageal squamous cell carcinomas (ESCC). This fragment overlaps with an expressed sequence tag mapped to 7q22. Further 5 0 and 3 0 -rapid amplification of cDNA ends revealed that it is part of a novel, single-exon gene with full-length mRNA of 2052 bp and encodes a nuclear protein of 109 amino acids (B15 kDa). This gene, designated as gene amplified in esophageal cancer 1 (GAEC1), was located within a 1-2 Mb amplicon at 7q22.1 identified by high-resolution 1 Mb array-comparative genomic hybridization in 6/10 ESCC cell lines. GAEC1 was ubiquitously expressed in normal tissues including esophageal and gastrointestinal organs; with amplification and overexpression in 6/10 (60%) ESCC cell lines and 34/99 (34%) primary tumors. Overexpression of GAEC1 in 3T3 mouse fibroblasts caused foci formation and colony formation in soft agar, comparable to H-ras and injection of GAEC1-transfected 3T3 cells into athymic nude mice formed undifferentiated sarcoma in vivo, indicating that GAEC1 is a transforming oncogene. Although no significant correlation was observed between GAEC1 amplification and clinicopathological parameters and prognosis, our study demonstrated that overexpressed GAEC1 has tumorigenic potential and suggest that overexpressed GAEC1 may play an important role in ESCC pathogenesis.
Introduction
Gene amplifications and overexpressions are among the major genomic aberrations involved in the esophageal squamous cell carcinomas (ESCC) pathogenesis (reviewed by Lam, 2000) . Our recent work of comparative DNA fingerprinting with inter-simple sequence repeat-polymerase chain reaction (ISSR-PCR) identified a series of amplifications and deletions in ESCC (Tang et al., 2001) . Further analysis of the amplified ISSR-PCR bands in ESCC led to the identification of a frequently amplified 357 bp sequence that showed an exact homology to an expressed sequence tag sequence (293 bp) at 7q22. The amplification of 7q22 has been reported in ESCC (Kwong et al., 2004) and many other cancers, including breast cancer (Forozan et al., 2000) , choriocarcinoma (Ahmed et al., 2000) , pancreatic carcinoma (Solinas-Toldo et al., 1996) , non-papillary renal-cell carcinoma (Yang et al., 2000) and T-cell leukemia (Ariyama et al., 1999) . Thus, 7q22 is involved in the tumorigenesis of a range of cancers.
Further molecular characterization of the 357-bp fragment in this study revealed that it is a part of a single-exon gene (2052 bp) frequently amplified and overexpressed in ESCC. We have designated it as gene amplified in esophageal cancer 1 (GAEC1). GAEC1 encodes a nuclear protein of 109 amino acids (B15 kDa). Overexpressed GAEC1 has tumorigenic potential, suggesting that it is a functional oncogene involved in ESCC pathogenesis.
Results

Molecular characterization of GAEC1
To obtain the full-length GAEC1 cDNA, 5 0 and 3 0 -rapid amplification of cDNA ends (RACE) were performed on RNA from ESCC cell line HKESC2 and immortalized normal esophageal epithelial cell line NE1 (Deng et al., 2004) The RACE reactions were performed on DNase-treated total RNA from HKESC2 using the RACE primers ( Figure 1A) . A major band of 1137 bp (product X) could be generated from the nested PCR of 3 0 -RACE. For 5 0 -RACE, two rounds of analysis were carried out. After sequencing of the RACE products (657 bp) from the first experiment (results not shown), new primers were designed to perform further 5 0 -RACE. Sequencing of these bands showed that they were all For the full-length GAEC1 mRNA (Figure 2) , there are three possible translation initiation sites in the deduced amino-acid sequence of GAEC1, one at nucleotide positions À87 to À85, a second at nucleotide positions À54 to À52, and a third at nucleotide positions 1 to 3. The third ATG codon is embedded in a Kozak sequence and is therefore favored to be the start codon (Kozak, 1987) . By comparing the cDNA sequence of GAEC1 with the known genomic clone (PAC76h2), the GAEC1 transcript was found to be an intronless cDNA composed of 2052 nucleotides with 327 bp of coding sequence and 1207 bp of 3 0 and 518 bp of 5 0 non-coding sequences (Figure 2 ). Several putative polyadenylation signals (Beaudoing et al., 2000) and a binding site of ARE-binding protein for RNA degradation can also be found in the 3 0 non-coding region.
GAEC1 was predicted to encode a novel protein of 109 amino acids with no homology to any known protein in the SwissProt database.
Amplification and overexpression of GAEC1 in ESCC GAEC1 amplification in ESCC was studied by semiquantitative PCR for 99 paired tumor (T) and nontumor (NT) specimens, 10 ESCC cell lines and NE1 cell line. The densitometric analysis showed that GAEC1 was amplified (band intensity ratio (T/N) >2-fold) in 34/99 (34%) tumors ( Figure 3A(a) ). In addition, GAEC1 amplification was observed in 6/10 (60%) cell lines (HKESC1, HKESC2, HKESC3, EC109, KYSE 70, KYSE 410) when compared with NE1 ( Figure 3B(a) ). The overexpression of GAEC1 mRNA was studied by semiquantitative reverse transcription-PCR (RT-PCR), using the DNA-free RNA from these ESCC specimens, ESCC cell lines and NE1. Results showed that the tumors Figure 2 Nucleotide and predicted amino-acid sequence of GAEC1. The 5 0 and 3 0 non-coding sequences ranged from À518 to À1 and 330 to 1534, respectively. The translation initiation codon (ATG) is underlined and italicized, and the stop codon (TGA) is underlined. GAEC1 contains a tract of six GTG trinucleotides repeats in its coding DNA and a track of four CAC trinucleotides in its 3 0 noncoding region (shown in bold letters). The Kozak sequence is shaded in grey, the putative polyadenylation signals are boxed, and the binding site of ARE-binding protein for RNA degradation is double-underlined.
with GAEC1 amplification also showed overexpression. The comparison of the band intensities between six ESCC cell lines with amplified GAEC1 and NE1 showed that the GAEC1 mRNA levels were upregulated by twofold or more in these cell lines (Figure 3 ).
Ten ESCC paired (T and NT) specimens were further analyzed by Southern blot hybridization ( Figure 3A(b) ) and the results were consistent with our semiquantitative PCR results of GAEC1 amplification ( Figure 3A(a) ). The single-sized product of 6.3 kb for GAEC1 is predicted by the EcoRI restriction sites surrounding the gene in genomic clone PAC76h2, in which there is no EcoRI site within GAEC1.
Northern blot hybridization was carried out using total RNA from 10 ESCC specimens. A GAEC1 singlesized mRNA transcript of 2052 bp was detected in tumors with overexpression ( Figure 3A(d) ). These results were consistent with our semiquantitative RT-PCR results of GAEC1 mRNA overexpression in tumors.
Mutational analysis of GAEC1 in ESCC
The sequencing results of the entire coding region of GAEC1 cDNA sequences from 99 paired (T and NT) specimens and 10 ESCC cell lines provided no evidence of alternatively spliced GAEC1 mRNAs, polymorphisms or somatic mutations of GAEC1 in ESCC.
Identification of a frequent amplicon containing GAEC1 at 7q22.1 in ESCC cell lines by 1 Mb array-comparative genomic hybridization We analyzed 10 ESCC cell lines for genomic DNA copy amplifications and losses, by using the high-resolution 1 Mb array-comparative genomic hybridization (CGH) system established by the Wellcome Trust Sanger Institute (Hurst et al., 2004; Ying et al., 2006) . Among the genetic changes detected (Ying and Tao, unpublished) , an amplicon of B1-2 Mb (defined by BAC clone RP11-401L13; was detected in 6/10 cell lines (HKESC1, HKESC2, HKESC3, EC109, KYSE70 and KYSE410) Figure 4a and b). This amplicon is located at 7q22.1 and contains the identified GAEC1 gene.
Expression of GAEC1 in normal tissues
The tissue distribution of GAEC1 expression was examined by performing multi-tissue Northern blot (MTN) analysis of the human digestive system and by screening multi-tissue cDNA (MTC) panels of other normal human tissues. In the MTN blot ( Figure 5A ), all of the selected organs showed a single-sized transcript of B2 kb, with no evidence of alternatively spliced GAEC1. Both MTN and MTC results showed transcripts of GAEC1 in all human tissues studied including the selected gastrointestinal organs. However, the levels of expression varied across different tissues. For instance, GAEC1 mRNA was highest in placenta, lung, spleen, small intestine and peripheral blood leukocytes ( Figure 5B ).
Transforming potential of GAEC1 in vitro
The transforming properties of GAEC1 on mouse 3T3 fibroblasts were assessed by the ability of the mock, pcDNA3.1-GAEC1 and pCMV-Ras vectors transfected cells to show anchorage-independent growth in soft agar ( Figure 6A ) and to form foci in monolayer culture ( Figure 6B ). The efficiency of colony formation in soft agar for each type of transfected 3T3 cell was plotted ( Figure 6A(d) ). The results showed that the number of colonies formed by GAEC1-transfected 3T3 cells in soft agar were comparable to the colonies formed by Rastransfected 3T3 cells, which was significantly more than the colonies formed by 3T3 cell transfected with the mock vector. These results were consistent with the observations obtained from monolayer culture experiment, which indicated that GAEC1-transfected 3T3 cells formed the highest number of colonies in monolayer culture, even slightly more than the Ras-transfected 3T3 cell, and were not contact inhibited ( Figure 6B ).
Cell proliferation assay was performed on stably transfected mouse 3T3 fibroblasts with mock, pcDNA3.1-GAEC1 or pCMV-Ras vectors, respectively ( Figure 6D ). The GAEC1-transfected cells proliferated more rapidly and had the shortest doubling time than RT-PCR using primers AA-1 and JAG-2 amplified a 186-bp fragment of the GAEC1 transcript in all tissues with different levels. b-actin amplification was used for normalizing the cDNA amount.
the mock vector or Ras-transfected 3T3 cells ( Figure 6D ). To eliminate the possibility that the increased proliferation effect was due to differential overexpression of GAEC1, two independent clones of pcDNA3.1-GAEC1 transfected 3T3 cells with either high (clone c1) or low (clone c2) GAEC1 expression ( Figure 6C) were studied by the cell proliferation assay. However, no significant difference was observed in cell proliferation rate of the clones 1 and 2 of the GAEC1-transfected 3T3 cells ( Figure 6D ).
Tumorigenic potential of GAEC1 in vivo
The tumorigenic potential of overexpressed GAEC1 in mouse 3T3 fibroblasts was evaluated in athymic nude mice in vivo. Subcutaneous injection with pcDNA3.1-GAEC1 and pCMV-Ras transfected 3T3 cells developed subcutaneous tumors in all tested nude mice, whereas the nude mice that received the mock pcDNA3.1(À) vector did not develop any subcutaneous tumor mass (Figure 7a ). The subcutaneous tumor mass developed from the GAEC1-transfected 3T3 cells showed the histopathological appearance of undifferentiated sarcomas (Figure 7b ). Overexpression of GAEC1 in the developed subcutaneous tumor in nude mice was confirmed by RT-PCR (Figure 7c ).
Expression of GAEC1 protein in vitro
The full-length coding region of GAEC1 was cloned into pcDNA3.1(-) vector and expressed using the in vitro transcription/translation system under the control of the T7 promoter. Autoradiography showed that the pcDNA3.1-GAEC1 vector construct encoded a 35 Slabelled protein with molecular weight of B15 kDa ( Figure 8A ). Empty vector and luciferase controls encoded either no protein or a protein of the expected molecular weight (B61 kDa) of luciferase, respectively.
Subcellular localization of GAEC1-GFP fusion protein
To determine the subcellular localization of GAEC1 protein in human embryonic kidney (HEK) 293 cells, the coding region of GAEC1 was first cloned into the pcDNA3.1/CT-green fluorescent protein (GFP)-TOPO vector and then transiently transfected and expressed in HEK 293 cells followed by analysis of subcellular localization patterns. Figure 8B shows that the GAEC1-GFP fusion protein was detected exclusively in the nucleus as aggregated foci in the inner nuclear region.
Clinicopathological correlation
The statistical analysis showed no significant correlation of GAEC1 amplification with histological differentiation (P ¼ 0.576), tumor staging (P ¼ 0.794) in 99 primary ESCC patients (Table 1a ) and overall survival (P ¼ 0.2628) in 83 Stage II and III cases (Table 1b) . Moreover, no significant correlation between the level of the GAEC1 gene amplification and clinicopathological grade and overall survival was observed even when the ESCC cases were further subdivided into four groups based on the levels of GAEC1 gene amplification (two, three, four or more folds; results not shown).
Discussion
We recently identified a 357 bp ISSR-PCR fragment at 7q22 that was frequently amplified in ESCC. Further molecular characterization of this fragment in this study showed that it is a part of a single-exon gene, GAEC1, with a mRNA of 2052 bp coding a nuclear protein of 109 amino acids (B15 kDa). GAEC1 was expressed in all the human normal tissues studied, including all the selected esophageal and gastrointestinal organs, although differentially. GAEC1 full-length mRNA encodes a protein of B15 kDa. The predicted GAEC1 protein from its cDNA sequence showed no homology to any known protein. However, clues to the GAEC1 protein functions can be inferred from its subcellular localization. The observation of GAEC1-GFP speckles in the inner nuclear region might indicate its significance in nuclear functions (Fujibe et al., 2006) . GAEC1 has one predicted target site for protein kinase C (PKC) phosphorylation at amino-acid residues 29-31 (S-G-K); PKC is a crucial regulator of cell cycle events and links signal transduction pathways to the cell cycle machinery (Watters and Parsons, 1999) . Examples include the activation of nuclear transcription factors and the regulation of cytoskeleton leading to cellular differentiation (Keenan and Kelleher, 1998) . In addition, GAEC1 also shows three target sites for phosphorylation by casein kinase II (CKII) located at the aminoacid residues 52-55 (S-H-E-D), 65-68 (T-M-Q-E) and 77-80 (S-S-E-E). CKII has been reported to involve in the regulation of nuclear oncoproteins, transcription factors and other enzymes involving in DNA metabolism (Litchfield and Luscher, 1993) . The features of these related kinases, also match with our findings of the nuclear localization of GAEC1 protein in mammalian cells.
Our array-CGH analysis showed that GAEC1 was indeed located within an amplicon of B1-2 Mb (defined by BAC clone RP11-401L13) at 7q22.1 in 6/10 ESCC cell lines studied. The genomic sequence (PAC76h2) of the 7q22 region, in which GAEC1 is located, has been previously mapped within the contig containing CUTL1 (CCAAT displacement protein and its splice variant) (Glockner et al., 1998) . Previously, we showed by cDNA expression array that mRNA of the CUTL1 gene was upregulated in both the HKESC1 and HKESC2 cell lines (Hu et al., 2001) . These observations parallel the current study, indicating that a few 7q22.1 genes may be amplified and overexpressed in ESCC.
Genomic amplification and overexpression of cancerrelated genes contribute to tumor pathogenesis by activating protooncogenes (Nowell, 1989) . Our present study demonstrates that GAEC1 is amplified and overexpressed in 34% of ESCC tumor and 60% of cell lines. Although no significant correlation was observed between GAEC1 amplification and clinicopathological parameters and prognosis in ESCC tumors, GAEC1 does functions as a transforming gene. Overexpression of GAEC1 mRNA in mouse 3T3 fibroblasts promoted cell proliferation and caused colony formation and anchorage-independent growth in soft agar in vitro. Moreover, subcutaneous injection of GAEC1-transfected 3T3 cells into athymic nude mice in vivo resulted in the formation of undifferentiated sarcoma in all the mice tested. These results support the notion that GAEC1 is a putative oncogene and that its overexpression contributes to the neoplastic phenotype of ESCC. The ubiquitous expression of this gene suggests that overexpressed GAEC1 may play a role in other cancers as well. 
Materials and methods
ESCC specimens and cell lines
Ninety-nine paired ESCC (T and NT) specimens, 10 ESCC cell lines (HKESC1, HKESC2, HKESC3, SLMT-1, EC1, EC18, EC109, KYSE 70, KYSE 410 and KYSE 520) were studied. One HPV16 E6E7 immortalized normal esophageal epithelial cell line (NE1) was used as a control.
RACE analyses
RNA samples were pretreated with DNase I (DNA-free; Ambion Inc., Austin, TX, USA) and the absence of DNA in these treated samples was confirmed by PCR amplification of genomic DNA sequence of b-globin using primers GH20 and PC04 (Greer et al., 1991) . 3 0 and 5 0 -RACE was performed using total RNA from HKESC2 and NE1 with the RACE kit (Roche, Mannheim, Germany). Figure 1A shows the primer position for RACE and their sequences are described in Supplementary Table 1 . The RACE products were cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and sequenced. Further 5 0 -RACE was performed using a new set of primers (5 0 -314 and 5 0 -197), designed based on the sequence of the previous 5 0 -RACE products.
PCR analyses
Semiquantitative PCR was carried out using 30 ng of genomic DNA and primers AA-1 and JAG-2 (Supplementary Table 1 ). The b-globin DNA sequence was also amplified in the same tube using the primers PC03 and PC04 (110 bp) (Greer et al., 1991) as an internal control. The histological differentiation data of one patient could not be retrieved.
Semiquantitative RT-PCR was carried out using 2 mg of DNA-free RNA using the GeneAmp RNA PCR kit (PE Applied Biosystems, Foster City, CA, USA) and AA-1 and JAG-2 primers (Figure 1; Supplementary Table 1) . The b-actin mRNA sequence was also amplified in the same tube as an internal control (Kang et al., 1996) . Semiquantitative RT-PCR for the human MTC panels, containing the cDNA generated from polyA þ RNA of 16 normal tissues (BD Biosciences Clontech, Palo Alto, CA, USA), was performed as described above.
Southern and Northern blot hybridization
For Southern blot, 20 mg of genomic DNA was digested with EcoRI (Promega), fractionated on 1% agarose gel and transferred to a nylon membrane (Hybond N þ ; Amersham Pharmacia, UK) and probed with 32 P-labelled GAEC1 cDNA probe generated by RT-PCR from NE1 (Figure 1 ; Supplementary Table 1 ). The product was cloned into pGEM-T vector, followed by plasmid purification and sequencing. The cDNA insert was isolated using EcoRI, and labelled as the GAEC1-specific probe. The b-globin probe (BD Biosciences Clontech) was used as a control for normalizing DNA amount.
For Northern blot analysis, 20 mg of total RNA was size fractionated in 1% agarose/2.2 M formaldehyde gel, transferred to nylon membrane (Hybond N þ ), and probed with the 32 P-labelled GAEC1 cDNA probe, with the labelled b-actin cDNA probe as a control.
Northern blot analysis for GAEC1 in 11 normal human gastrointestinal tissues was performed using the premade MTN blot membrane, which included polyA þ RNA (2 mg) derived from each tissue (BD Biosciences Clontech).
Mutational analysis
To detect any polymorphisms or mutations in the GAEC1 coding sequence, cDNAs were synthesized using DNA-free RNAs and the entire coding region was amplified employing the Expand High Fidelity PLUS Enzyme system (Roche) and primers GAEC1-F and GAEC1-R ( Figure 1A ; Supplementary Table 1 ). The products were purified and sequenced directly.
Array-CGH 1-Mb resolution whole-genome arrays were provided by the Sanger Institute, UK (http://www.sanger.ac.uk/Projects/ Microarrays/). Array-CGH was performed as described (Hurst et al., 2004; Ying et al., 2006) .
GAEC1-expression plasmid and cell transfection
The complete coding region of GAEC1 containing a Kozak translation initiation sequence, an ATG start codon and a TGA stop codon, was amplified from the DNA-free RNA from HKESC2 using primers NC-F and NC-R ( Figure 1A ; Supplementary Table 1) and cloned into pGEM-T vector. The cDNA insert was then subcloned into the expression vector pcDNA3.1(-) (Invitrogen Corporation, Carlsbad, CA, USA) and sequence confirmed.
Swiss albino mouse fibroblasts 3T3 were transfected with the mock, pcDNA3.1-GAEC1 and pCMV-Ras (constitutively expresses the wild-type (wt) Ha-ras protein; BD Biosciences Clontech) vectors using FuGene 6 (Roche) with G418 selection. Transfection efficiency was approximately 10% (Ince et al., 2000) .
In vitro growth properties assays The ability of GAEC1 to induce transformation in vitro was evaluated by the colony formation efficiency of transfected mouse 3T3 fibroblasts in monolayer culture and soft agar assay (Ying et al., 2006) . The effect of overexpressed GAEC1 on cell proliferation in vitro was examined using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) at various time points (Ying et al., 2006) . Two independent clones of pcDNA3.1-GAEC1-transfected 3T3 cells with high (clone c1) or low (clone c2) expression were expanded and used. The experiment was performed in replicates of three wells and repeated at least three times. Colorimetric assay by spectrophotometry was used to determine the number of proliferating cells. This assay is based on the bioreduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium by metabolically active cells to a form a product, in the presence of phenazine methosulfate, that is soluble in tissue culture medium and can be measured by spectrophotometry. The quantity of formazan product is directly proportional to the number of living cells in culture.
In vivo tumorigenicity assays A tumorigenecity test of the three transfected constructs (mock vector, pcDNA3.1-GAEC1, and pCMV-Ras) was performed using four athymic nude mice for each of the constructs. Approximately 5 Â 10 6 of transfected 3T3 cells selected in G418 were injected subcutaneously into the flanks of female athymic nude mice. The animals were examined daily, up to 45 days, for the development of subcutaneous tumor mass. The tumors were dissected and fixed in formalin for histopathological examination.
In vitro transcription/translation assay The [ 35 S]methionine labelled protein product of GAEC1 was detected using the plasmid (pcDNA3.1-GAEC1) and TNT Quick Coupled Transcription/Translation Systems (Promega) under control of the T7 promoter. Prestained protein molecular weight markers (Fermentas International Inc., Ontario, Canada) were used to estimate the molecular weight of proteins.
Transient transfection of HEK 293 cells
The GAEC1 cDNA was subcloned in frame with Cycle 3 GFP of the pcDNA3.1/CT-GFP-TOPO. vector from the CT-GFP Fusion TOPO TA Expression Kit (Invitrogen). The recombinant vector allowed expression of GAEC1 with Cycle 3 GFP fused to its C-terminus. The insert orientation and sequence were confirmed by sequencing. Expression of the fusion protein was assessed by transient transfection in HEK 293 cells using FuGene 6 (Roche). A control vector (pcDNA3.1/ CT-GFP) was used to check transfection efficiencies and expression of Cycle 3 GFP. After 48 h post-transfection, the cells on coverslips were labelled with a Hoechst 33342 dye (Invitrogen) for DNA stain, and fixed with 3.7% formaldehyde before fluorescence microscopy. Images were captured with a Nikon C-SHG camera controlled with an ACT-2U software (Nikon Instruments, Melville, NY, USA).
Clinicopathological correlation
The relationship between GAEC1 amplification and clinicopathologic parameters was analyzed in 99 primary ESCC, and overall survival in 83 Stage II and II cases. Statistical analysis was performed using SPSS for Windows Release 13.0. (SPSS Inc., Chicago, IL, USA). For analyzing correlations between categorical variables, Fisher's exact test was used. A two-tailed probability (P-value o0.05) was considered as statistically significant.
